Furthermore, reducing IFI16 levels directly mitigated markers of cell injury and enhanced viability in vitro, supporting a detrimental role for the DDR-IFI16 axis in contributing to both fibrosis and cellular damage in the context of cardiomyopathy. This evidence concerns the gene IFI16 and cardiomyopathy.